$1583 | SAVE $216 | Single User
$4749 | SAVE $648 | Enterprise License

Benign Prostatic Hyperplasia - Pipeline Drugs and Companies, Q2 2019
[Report Updated: 08-04-2019]

Published by VPA Research: 08 Apr 2019 | 235199 | In Stock
Related Topics: Healthcare

Introduction

Summary

Benign Prostatic Hyperplasia pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Benign Prostatic Hyperplasia R&D activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.

Extensive Coverage of Pipeline Candidates

The Benign Prostatic Hyperplasia report covers all the pre-clinical compounds and clinical compounds under evaluation for treatment of Benign Prostatic Hyperplasia as of 2019. All preclinical, research, discovery, pre registration, phase 1, phase 2, and phase 3 trials active are included in the study.

Over 10 descriptive details provided for each Pipeline Product

Complete analysis of therapeutics for treatment of Benign Prostatic Hyperplasia with details of current status of development, pipeline phase, drug target, mechanism of action (MoA), route of administration (RoA), participating companies, originator, collaborators and molecule type are included. The study also covers the historic developments, pharmacological action and recent developments associated with each drug.

Companies participating in Benign Prostatic Hyperplasia pipeline Profiled in detail

Key players actively participating in Benign Prostatic Hyperplasia pipeline are profiled along with their R&D progress in Benign Prostatic Hyperplasia treatment are provided. Companies /Universities /Institutes participating as originators, collaborators, licensors, investors, and marketing or developing companies are detailed in the report. Further, for all the developing companies, detailed profile is also provided.

Information Sourced from in-house Proprietary Databases

The report is developed using information from in-house database developed over years through daily updates from company reports, websites, events, conferences, news, announcements, clinical trial registries, regulatory authorities, universities and industry associations.

Report assists users in taking actionable steps

Benign Prostatic Hyperplasia pipeline report enables users to gain clear understanding into large and small companies participating in the pipeline and detailed insights into their product portfolio. The guide presents also available opportunities for new business in Benign Prostatic Hyperplasia treatment pipeline.

The report includes:

• The research work provides comprehensive overview of Benign Prostatic Hyperplasia pipeline and treatment landscape

• Complete list of drug candidates from discovery to pre-registration phases are analyzed

• Companies and universities participating in the pipeline are analyzed in detail along with their drug development product portfolio

• Detailed drug profiles of Benign Prostatic Hyperplasia pipeline compounds including status, phase, mechanism of action, route of administration, originators, licensing and collaborating companies, grants, technological advancements and investments are detailed

• Research and Development progress and trial details, results wherever available, are also included in the Benign Prostatic Hyperplasia pipeline study

• All recent news and developments related to Benign Prostatic Hyperplasia drugs are provided

Table of Contents
for Benign Prostatic Hyperplasia - Pipeline Drugs and Companies, Q2 2019 [Report Updated: 08-04-2019]

  • 1. Introduction

    1.1. Pipeline Snapshot, 2019

    1.2. Overview Pipeline Activities in 2019

    2. Benign Prostatic Hyperplasia Disease Overview

    3. Benign Prostatic Hyperplasia R&D Pipeline Trends

    3.1. Pipeline Drugs under development by phase, 2019

    3.2. Pipeline Drugs by Mechanism of Action, 2019

    3.3. Pipeline Drugs by Route of Administration, 2019

    3.4. Pipeline Drugs by Company, 2019

    3.5. Pipeline Drugs by Molecule Type, 2019

    4. Benign Prostatic Hyperplasia Pre-clinical and Discovery Phase Drug Profiles

    4.1. Drug Name/Alternative Names

    4.2. Originator

    4.3. Licensor/Developer/Collaborators

    4.4. Class

    4.5. Mechanism of Action

    4.6. Route of Administration

    4.7. Orphan Drug Status

    4.8. New Molecular Entity

    4.9. Current Status

    4.10. Trial Landscape

    4.11. Development History

    5. Benign Prostatic Hyperplasia Clinical Phase Drug Profiles

    5.1. Drug Name/Alternative Names

    5.2. Originator

    5.3. Licensor/Developer/Collaborators

    5.4. Class

    5.5. Mechanism of Action

    5.6. Route of Administration

    5.7. Orphan Drug Status

    5.8. New Molecular Entity

    5.9. Current Status

    5.10. Trial Landscape

    5.11. Development History

    6. Company Profiles

    6.1. Benign Prostatic Hyperplasia companies

    6.1.1. Business Profile

    6.1.2. Pipeline Products

    6.1.3. Benign Prostatic Hyperplasia Activities

    7. Recent News Landscape

    8. Appendix

    8.1. Sources and Research Methodology

    8.2. Publisher Expertise

    8.3. Database and Custom Services

Additional Details

Publisher

VPA Research

Publisher Information

VPAResearch pipeline research is one of the reputed and trusted series worldwide. Our coverage includes- 42000+ pipeline drugs in our internal databases All databases updated daily by our in-house experts crawling through  10,000+ sources. In-depth analysis of end-to-end pipeline development included

Reference

235199 | VPA0419P080

Number of Pages

89

Report Format

PDF

VPA Research Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 12% today! Benign prostatic hyperplasia (BPH) - Epidemiology Forecast To 2023
DelveInsight “Benign prostatic hyperplasia (BPH) - Epidemiology Forecast To 2023” provides an overvi...
31 May 2017 by Delve Insight USD $2,420 (normally
USD $2,750)
More Info
SAVE 12% today! Benign Prostatic Hyperplasia - Pipeline Review, H1 2017
Benign Prostatic Hyperplasia - Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest Pharmac...
30 May 2017 by Global Markets Direct USD $1,760 (normally
USD $2,000)
More Info
SAVE 12% today! Benign Prostatic Hyperplasia-API Insights, 2017
The active pharmaceutical ingredients worldwide market is in continuous development from the recent ...
30 May 2017 by Delve Insight USD $1,100 (normally
USD $1,250)
More Info
SAVE 12% today! Benign prostatic hyperplasia (BPH)- Market Insights, Epidemiology and Market Forecast-2023
Note*: This report requires 5-7 business days to complete.DelveInsight’s Benign prostatic hyperplasi...
30 May 2017 by Delve Insight USD $4,356 (normally
USD $4,950)
More Info
SAVE 12% today! Benign Prostatic Hyperplasia Global Clinical Trials Review, H1, 2017
Benign Prostatic Hyperplasia Global Clinical Trials Review, H1, 2017SummaryGlobalData's clinical tri...
30 Apr 2017 by Global Data USD $2,200 (normally
USD $2,500)
More Info
SAVE 12% today! Nephrology And Urology Devices Market Global Briefing 2017 Including: Dialysis Devices, Urinary Stone Devices, Benign Prostatic Hyperplasia (BPH) Treatment Devices, and Endoscopy Devices Covering: Baxter, Fresenius Medical Care, Cook Group Incorporated, B. Braun Group, Nxstage Medical Inc., and Rockwell Medical Inc.
Nephrology and urology devices are used in the treatment and diagnosis of diseases related to kidney...
06 Feb 2017 by The Business Research Company USD $880 (normally
USD $1,000)
More Info
SAVE 12% today! Benign Prostatic Hyperplasia Global Clinical Trials Review, H2, 2016
Benign Prostatic Hyperplasia Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical tri...
28 Sep 2016 by Global Data USD $2,200 (normally
USD $2,500)
More Info
SAVE 12% today! Urology Surgical Instruments Market by Product (Endoscopes, Endovision Systems, Peripheral Instruments, Consumables and Accessories), Application (Chronic Kidney Diseases, Benign Prostatic Hyperplasia, Oncology) - Global Forecast to 2021
The global urology surgical instruments market is expected to reach USD 11.48 billion by 2021 from U...
01 Sep 2016 by MarketsandMarkets USD $4,972 (normally
USD $5,650)
More Info
SAVE 12% today! Benign Prostatic Hypertrophy Forecast in 17 Major Markets 2016-2026
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Benign Prostatic Hypertrophy (BP...
01 Mar 2016 by Black Swan Analysis USD $5,368 (normally
USD $6,100)
More Info
SAVE 12% today! OpportunityAnalyzer: Benign Prostatic Hyperplasia - Opportunity Analysis and Forecast to 2024
OpportunityAnalyzer: Benign Prostatic Hyperplasia - Opportunity Analysis and Forecast to 2024Summary...
08 Sep 2015 by Global Data USD $8,356 (normally
USD $9,495)
More Info

This report is published by VPA Research

VPAResearch pipeline research is one of the reputed and trusted series worldwide. Our coverage includes- 42000+ pipeline drugs in our internal databases All databases updated daily by our in-house experts crawling through  10,000+ sources. In-depth analysis of end-to-end pipeline development included

Download Free Report Summary PDF

Benign Prostatic Hyperplasia - Pipeline Drugs and Companies, Q2 2019 [Report Updated: 08-04-2019] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...